Pharmacologic activation of autophagy without direct mTOR inhibition as a therapeutic strategy for treating dry macular degeneration
Open Access
- 19 April 2021
- journal article
- research article
- Published by Impact Journals, LLC in Aging
- Vol. 13 (8) , 10866-10890
Abstract
Dry age-related macular degeneration (AMD) is marked by the accumulation of extracellular and intracellular lipid-rich deposits within and around the retinal pigment epithelium (RPE). Inducing autophagy, a conserved, intracellular degradative pathway, is a potential treatment strategy to prevent disease by clearing these deposits. However, mTOR inhibition, the major mechanism for inducing autophagy, disrupts core RPE functions. Here, we screened autophagy inducers that do not directly inhibit mTOR for their potential as an AMD therapeutic in primary human RPE culture. Only two out of more than thirty autophagy inducers tested reliably increased autophagy flux in RPE, emphasizing that autophagy induction mechanistically differs across distinct tissues. In contrast to mTOR inhibitors, these compounds preserved RPE health, and one inducer, the FDA-approved compound flubendazole (FLBZ), reduced the secretion of apolipoprotein that contributes to extracellular deposits termed drusen. Simultaneously, FLBZ increased production of the lipid-degradation product β-hydroxybutyrate, which is used by photoreceptor cells as an energy source. FLBZ also reduced the accumulation of intracellular deposits, termed lipofuscin, and alleviated lipofuscin-induced cellular senescence and tight-junction disruption. FLBZ triggered compaction of lipofuscin-like granules into a potentially less toxic form. Thus, induction of RPE autophagy without direct mTOR inhibition is a promising therapeutic approach for dry AMD.Keywords
This publication has 116 references indexed in Scilit:
- Balancing the fat: lipid droplets and human diseaseEMBO Molecular Medicine, 2013
- DRAM1 Regulates Autophagy Flux through LysosomesPLOS ONE, 2013
- Autophagy modulation as a potential therapeutic target for diverse diseasesNature Reviews Drug Discovery, 2012
- P38 MAP kinase functions as a switch in MS-275-induced reactive oxygen species-dependent autophagy and apoptosis in Human colon Cancer cellsFree Radical Biology and Medicine, 2012
- Lipid Metabolism and Toxicity in the HeartCell Metabolism, 2012
- Linking lipids to Alzheimer's disease: cholesterol and beyondNature Reviews Neuroscience, 2011
- Discovery of 1-(4-(4-Propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-one as a Highly Potent, Selective Mammalian Target of Rapamycin (mTOR) Inhibitor for the Treatment of CancerJournal of Medicinal Chemistry, 2010
- Retinal ultrastructure of murine models of dry age-related macular degeneration (AMD)Progress in Retinal and Eye Research, 2010
- Novel targets for Huntington's disease in an mTOR-independent autophagy pathwayNature Chemical Biology, 2008
- The lipofuscin fluorophore A2E perturbs cholesterol metabolism in retinal pigment epithelial cellsProceedings of the National Academy of Sciences, 2007